Good Morning My FRiends,
Thought the following information may be of some benefit
FDA Advisory Committee Backs Approval Of Doxorubicin For Ovarian
Cancer
SILVER SPRING, MD, Jun 09 (Reuters Health) - Advisers to the US
Food and Drug Administration (FDA) on Tuesday voted 9-2 to back
accelerated approval of a liposomal formulation of doxorubicin
(Doxil) for ovarian cancer that is refractory to platinum- and
paclitaxel-based chemotherapy regimens. Doxil, to be sold by
Alza Corp. in the US, was approved by the FDA in 1995 for AIDS-
related Kaposi's sarcoma, and is also available in Europe,
Australia, and New Zealand. It is not approved anywhere for
ovarian cancer.
http://ipn.intelihealth.com/ipn/ihtIPN?c=228557
God Bless All,
marty auslander
------------------------------------------------------------------------
This is an automatically-generated notice. If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------
